STEP-HFpEF

What is STEP-HFpEF?

Semaglutide 2.4 mg in heart failure with preserved ejection fraction plus obesity (Kosiborod et al., NEJM 2023), with substantial gains in KCCQ clinical summary score and six-minute walk distance.

It was the first GLP-1 trial to show a heart-failure-specific symptomatic benefit, beyond event reduction alone.

Related reading: STEP-HFpEF: Measuring How People Actually Feel

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where STEP-HFpEF comes up on this site

On GLP Watchdog, STEP-HFpEF comes up in 1 tool.

Other terms under trial

• SURMOUNT-5
• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SCALE Maintenance

Where the evidence lives

• The full GLP-1 glossary (150 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers